DanielAaronPollyeaMD

PubMed

• Response to intensive induction chemotherapy after failure of frontline azacitidine and venetoclax in acute myeloid leukemia.
  Kellen B Gil, Diana Abbott, Maria L Amaya, Marc Schwartz, Jonathan A Gutman
  Leukemia & Lymphoma. 2024-12-01
• 5 citations
  Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine.
  Hartmut Döhner, Keith W Pratz, Courtney D DiNardo, Andrew H Wei, Brian A Jonas
  Blood. 2024-11-21
• Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML.
  Curtis A Lachowiez, Vishvaas I Ravikumar, Jad Othman, Jenny O'Nions, Daniel T Peters
  Blood. 2024-11-01

Journal Articles

• Randomized Comparison of Low Dose Cytarabine with or Without Glasdegib in Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome  
  Daniel Pollyea, MD, Nature
• Venetoclax with Azacitidine Disrupts Energy Metabolism and Targets Leukemia Stem Cells in Patients with Acute Myeloid Leukemia  
  Daniel A Pollyea, Jonathan A Gutman, Enkhtsetseg Purev, Clayton Smith, Nature
• Venetoclax Combined with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia  
  Brian A Jonas, Courtney D DiNardo, Olga Frankfurt, Daniel A Pollyea, Keith Pratz, Anthony Letai, Martha Arellano, Marina Konopleva, Hagop M Kantarjian, Blood
• Functional Genomic Landscape of Acute Myeloid Leukaemia  
  Marc M Loriaux, Christopher R Cogle, Patricia Kropf, Daniel A Pollyea, Uma Borate, Michael W Deininger, Nature
• Article Subversion of Systemic Glucose Metabolism as a Mechanism to Support the Growth of Leukemia Cells  
  Natalie J Serkova, Daniel A Pollyea, Enkhtsetseg Purev, ScienceDirect
• Next-Generation Sequencing and Eating of the Tree of Knowledge  
  Daniel Pollyea, MD, Clinical Cancer Research
• Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML  
  Daniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine
• Join now to see all

Abstracts/Posters

• A Phase 2 Study of Glasdegib for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with High Risk of Post-Allogeneic Stem Cell Transplantat...
  Daniel A Pollyea, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Interim Results from the Phase I Deplethink Trial Evaluating the Infusion of a NKG2D CAR T-Cell Therapy Post a Non-Myeloablative Conditioning in Relapse or Refractory ...
  Daniel A Pollyea, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based TherapiesClinically Relevant Abstract
  Daniel A Pollyea, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Management of Neutropenia during Venetoclax-Based Combination Treatment in Patients with Newly Diagnosed Acute Myeloid Leukemia
  Daniel A Pollyea, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Incidence of Serious Adverse Events, Pneumonitis, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphom...
  Daniel A Pollyea, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes Following Allogeneic Stem Cell Transplantation for AML in First Completion Remission Are Comparable between MRD Negative Patients and MRD Positive Patients Re...
  Daniel A Pollyea, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Inhibition of Fatty Acid Metabolism Re-Sensitizes Resistant Leukemia Stem Cells to Venetoclax with Azacitidine
  Daniel A Pollyea, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodyspl...
  Daniel A Pollyea, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Venetoclax and Azacitidine for Older Newly Diagnosed Patients with Acute Myeloid Leukemia: A Single-Institution Pilot Study Using Measurable Residual Disease to Guide ...
  Daniel A Pollyea, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Developmental Plasticity of Acute Myeloid Leukemia Mediates Resistance to Venetoclax-Based Therapy
  Daniel A Pollyea, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Data + Perspectives: Exploring the Role of Novel Agents and Emerging Strategies in the Management of Acute Myeloid Leukemia 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Acute Myeloid Leukemia: Moving Beyond 7+3 
  60th American Society of Hematology Annual Meeting - 12/1/2018
• Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Tracking of AML-Associated Mutations Via Droplet Digital PCR Is Predictive of Outcomes Post-Transplant 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• WT1 and BCORL1 Identified By Computational Biology Modeling Analysis of Patient Genomics Are Novel Predictors of Response to Azacitidine (AZA) and Lenalidomide (LEN) T... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ivosidenib (IVO; AG-120) in mutant IDH1 relapsed/refractory acute myeloid leukemia (R/R AML): Results of a phase 1 study. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
• Join now to see all